FY 2020 Funding Opportunity Announcement
OMH has released the following funding opportunity announcement for which applications are now being accepted. Announcement Number: MP-CPI-20-002 The Demonstration to Increase Hydroxyurea Prescribing for Children with Sickle Cell Disease Through Provider Incentives initiative supports projects to demonstrate the feasibility and effectiveness of providing financial incentives to providers to improve the quality of life of children with sickle cell disease (SCD) through increased prescription rates of hydroxyurea. OMH intends projects funded under this initiative to build the capacity of State Medicaid Offices and other partners to achieve three main goals: (1) develop performance measures for hydroxyurea prescribing for the three main provider types that care for children with SCD (i.e., hematologists, primary care providers, and emergency clinicians); (2) develop and implement an incentive payment system(s) for each provider type; and (3) evaluate the effectiveness of financial incentives for providers to increase hydroxyurea prescribing and decrease emergency department visits for children with SCD. OMH expects awarded projects to generate data and assess the impact of incentive payments on hydroxyurea prescribing behavior and the identification of best practices and lessons learned through the implementation of funded projects. Learn more about this FOA and how to apply. A technical assistance webinar for applicants will be held on July 31, 2020 from 2-3 pm ET. Click here to register for the webinar. |
Wednesday, July 29, 2020
New FY 2020 Funding Opportunity Announcement
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment